Product Description
Huperzia Serrata (TCM = Qian Ceng Ta/Jin Bu Huan) is a plant known as a firmoss that contains the acetylcholinesterase inhibitor huperzine A. It is widely distributed over-the-counter as a nootropic and dietary supplement.
This species is native to China, India, and Southeast Asia.
Huperzine A is a reversible acetylcholinesterase inhibitor and NMDA receptor antagonist that crosses the blood-brain barrier. A 2013 meta-analysis found that huperzine A may be efficacious in improving cognitive function, global clinical status, and activities of daily living for individuals with Alzheimer's disease.
Huperzine A is also marketed as a dietary supplement with claims made for its ability to improve memory and mental function. Huperzine A may also have a possible role in the treatment of myasthenia gravis.
| Product name: |
Huperzia serrata Extract |
| Active ingredients: |
Huperzine-A (CAS 120786-18-7)
Huperzine-B (CAS 103548-82-9) |
| Specification: |
0.5% 1% 5% 98% 99% |
| Service |
Free sample, Ready to Ship, Drop Shipping service,
Excellent Customs clearance Ability
MSDS, COA,TDS available
OEM Capsule form |
M.F.: C15H18N2O
M.W.: 242.316
Appearance: brown-yellow to off-white powder
Advantage
1) Both Natural and Synthetic huperzine-A are available
2) Free sample, MOQ 10grams
3) Ready to ship and drop shipping, In stock
4) Leading manufacturer of huperzia serrata extract
5) COA, MSDS, TDS, MOA, Flowchart, COMPOSITION BREAKDOWN, Chromatogram and other documents
6) Plant ID test,Carbon 14 test, HPLC test, 1% to 99% huperzine-A, 0.1% huperzine-B
7) OEM service, capsule and tablets available
Function and application
1)Treating myasthenia gravis;
2)Treating age-related memory decline and Alzheimer's disease;
3)HuperzineA can help young people with learning disabilities;
4)Memory enhancement.
Huperzine A is a powerful and reversible cholinesterase inhibitor. The effect of treating myasthenia gravis is similar to neostigmine, and the duration of the effect is significantly longer than neostigmine, with low toxicity and less adverse reactions. Huperzine A can significantly improve the cognitive function, behavior and mood disorders, activities of daily living, and overall function of AD patients, with good safety. It is suitable for benign memory disorders and improves the ability of patients to point to memory, associative learning, image recall, meaningless figure recognition, and portrait recall. It can also improve the memory impairment caused by dementia patients and brain organic diseases
Pharmacological Actions
This product is an extract from huperziaserrata (Thunb) Trev (huperziaserrata) of Huperzia family, which can promote memory reproduction and enhance memory retention. Its action characteristics are similar to neostigmine, but it has the following advantages: it has selective inhibition on true cholinesterase, and the inhibition intensity is thousands of times that of pseudocholinesterase; The inhibition mode is a mixture of competitive and non competitive inhibition, which is significantly different from the simple competitive inhibitor; It is easy to enter the center through the blood-brain barrier and has central and peripheral therapeutic effects; Long effective time; Good absorption from gastrointestinal tract; High safety index; Good stability.
The potency of ache was compared among different drugs.
The results were: huperzine a > physostigmine > neostigmine > huperzine B > Gal; The inhibitory intensity of BuChE was: physostigmine > neostigmine > huperzine a > huperzine B. The effect of this product on strengthening the muscle contraction amplitude caused by indirect electrical stimulation of nerves and enhancing the memory function of rats is stronger than that of physostigmine, but the toxicity is lower than that of physostigmine, and the action time is long.
Pharmacokinetics
The blood concentration time curve of rats after intraperitoneal injection or oral administration was analyzed to conform to the two compartment open model, intravenous or oral administration t1/2 α 6.7min and 9.8min respectively. t1/2 β 121.6min and 247.5min respectively. 15min after intravenous injection, the contents of kidney and liver were the highest, followed by lung, spleen, adrenal gland, heart fat and brain. After 24 hours, the content in various organs is close to trace, and a small amount of drugs can enter the fetus through the placenta. After administration, this product is mainly discharged through the kidney, 73.6% of the dosage is discharged in 24h, and 2.8% ± 1.2% of the dosage is discharged from feces. The total excretion within 7 days was 86.1% of the injection volume, some of which were metabolites.
Contraindication
People with bradycardia, or bronchial asthma, please in accordance with the doctor when taking huperzine-A
Clinical assessment
This verification adopts the international and domestic standardized assessment. The results show that the total effective rate of Huperzine A in improving the memory of benign memory disorders is 86.6%, of which the marked rate is 83.6%, the effective rate is 3.0%, and the total effective rate of the Naofukang group is 52.9%, of which The markedly effective rate was 41.1% and the effective rate was 11.8%; the total effective rate of Huperzine A in improving memory in the organic dementia group was 61.0%, of which the markedly effective rate was 43.8%, the effective rate was 17.2%, and the total effective rate in the Naofukang group was 46.8%. Among them, the markedly effective rate was 42.6%, and the effective rate was 4.2%; the total effective rate of Huperzine A in improving cognitive function was 53.2%, of which the markedly effective rate was 43.8%, and the effective rate was 9.4%; the total effective rate of the Naofukang group was 51.0%, of which the markedly effective rate 34.0%, the effective rate was 17.0%; the effective rate of Huperzine A in improving mood and behavioral disorders was 65.2%, and the effective rate of the Naofukang group was 36.1%.
The clinical verification results prove that huperzine A has a positive effect on the memory improvement of benign memory disorders, has a good effect on the memory improvement of brain organic memory disorders and dementia, and also has a certain effect on the improvement of emotional behavior disorders. The clinical dosage is 100-200μg/time, bid or tid, and the maximum is not more than 450 μg/d. At this dose, there is no serious toxicity and side effects, and there is no damage to the heart, liver and kidney functions.
Certifications
Packaging & Shipping
Company Profile
Shaanxi Afterglow Bioindustry Co.,Ltd was established in 2006, and located in Shaanxi Province, China. We are professional supplier of Fine chemicals, raw material for cosmetics, Food Additives, Nutritional supplement, Herbal/Animal Extract and Essential Oil.
As the predecessor of the County Institute of Traditional Chinese Medicine,We offer various OEM services with GMP standards, Meanwhile, the factory is equipped with the researching and quality test laboratory, and we have good relationship with several universities.
With more than ten years of export experience, quick response, good after-sale service, high product quality, and reasonable prices are the concepts that we always insisted on.
We uphold a consistent level of professionalism, quality, reliability and service, therefore we are always ready for cooperation and gladly welcome you.
Audited Supplier 
){kind=link}